These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11225647)

  • 1. Metabolic effects of moxonidine and other centrally acting antihypertensives.
    Schachter M
    Diabetes Obes Metab; 1999 Nov; 1(6):317-22. PubMed ID: 11225647
    [No Abstract]   [Full Text] [Related]  

  • 2. Centrally acting imidazoline I1-receptor agonists: do they have a place in the management of hypertension?
    van Zwieten PA
    Am J Cardiovasc Drugs; 2001; 1(5):321-6. PubMed ID: 14728014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central imidazoline (I1) receptors as targets of centrally acting antihypertensives: moxonidine and rilmenidine.
    van Zwieten PA
    J Hypertens; 1997 Feb; 15(2):117-25. PubMed ID: 9469786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological properties of the central antihypertensive agent, moxonidine.
    Edwards LP; Brown-Bryan TA; McLean L; Ernsberger P
    Cardiovasc Ther; 2012 Aug; 30(4):199-208. PubMed ID: 21884003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of sympathoinhibition by imidazolines.
    Szabo B; Urban R
    Ann N Y Acad Sci; 1995 Jul; 763():552-65. PubMed ID: 7677373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the baroreceptor-heart rate reflex effects of moxonidine, rilmenidine and clonidine in conscious rabbits.
    Godwin SJ; Tortelli CF; Parkin ML; Head GA
    J Auton Nerv Syst; 1998 Oct; 72(2-3):195-204. PubMed ID: 9851569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central I1-imidazoline receptors as targets of centrally acting antihypertensive drugs. Clinical pharmacology of moxonidine and rilmenidine.
    Van Zwieten PA; Peters SL
    Ann N Y Acad Sci; 1999 Jun; 881():420-9. PubMed ID: 10415946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Central nervous system as a target for the new antihypertensive agents].
    Nurminen ML
    Duodecim; 1999; 115(20):2267-73. PubMed ID: 11973931
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanism of the sympathoinhibition produced by the clonidine-like drugs rilmenidine and moxonidine.
    Szabo B; Bock C; Nordheim U; Niederhoffer N
    Ann N Y Acad Sci; 1999 Jun; 881():253-64. PubMed ID: 10415923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of the antihypertensive efficacy of and tolerance to 2 imidazoline receptor agonists: moxonidine and rilmenidine in monotherapy].
    Camilleri G; Portal B; Quiniou G; Clerson P
    Ann Cardiol Angeiol (Paris); 2001 Apr; 50(3):169-74. PubMed ID: 12555509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moxonidine: a review of its use in essential hypertension.
    Fenton C; Keating GM; Lyseng-Williamson KA
    Drugs; 2006; 66(4):477-96. PubMed ID: 16597164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The renaissance of centrally acting antihypertensive drugs.
    van Zwieten PA
    J Hypertens Suppl; 1999 Aug; 17(3):S15-21. PubMed ID: 10489094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the receptor involved in the central hypotensive effect of rilmenidine and moxonidine.
    Bock C; Niederhoffer N; Szabo B
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Apr; 359(4):262-71. PubMed ID: 10344524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel mechanism of action for hypertension control: moxonidine as a selective I1-imidazoline agonist.
    Ernsberger P; Haxhiu MA; Graff LM; Collins LA; Dreshaj I; Grove DL; Graves ME; Schäfer SG; Christen MO
    Cardiovasc Drugs Ther; 1994 Mar; 8 Suppl 1():27-41. PubMed ID: 8068578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs acting on imidazoline receptors: a review of their pharmacology, their use in blood pressure control and their potential interest in cardioprotection.
    Bousquet P; Feldman J
    Drugs; 1999 Nov; 58(5):799-812. PubMed ID: 10595861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of imidazoline antihypertensive drugs on sympathetic tone and noradrenaline release in the prefrontal cortex.
    Szabo B; Fritz T; Wedzony K
    Br J Pharmacol; 2001 Sep; 134(2):295-304. PubMed ID: 11564647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Possibilities of the use of moxonidine in the treatment of arterial hypertension in patients with metabolic syndrome and diabetes].
    Minushkina LO
    Kardiologiia; 2011; 51(4):74-8. PubMed ID: 21623724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imidazoline receptor agonist drugs: a new approach to the treatment of systemic hypertension.
    Yu A; Frishman WH
    J Clin Pharmacol; 1996 Feb; 36(2):98-111. PubMed ID: 8852385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New, modern, centrally active antihypertensive agents in the treatment of essential hypertension].
    Sevcík J; Masek K
    Cas Lek Cesk; 1999 Jun; 138(12):359-62. PubMed ID: 10566202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology of drugs acting on imidazoline and adrenergic receptors. Studies with clonidine, moxonidine, rilmenidine, and atenolol.
    Reid JL; Panfilov V; MacPhee G; Elliott HL
    Ann N Y Acad Sci; 1995 Jul; 763():673-8. PubMed ID: 7677387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.